HMGN1 Plays a Significant Role in CRLF2 Driven Down Syndrome Leukemia and Provides a Potential Therapeutic Target in This High-Risk Cohort

Investigators demonstrated that HMGN1 knockout-mitigated leukemic phenotypes including hepatosplenomegaly, thrombocytopenia, and anemia, were commonly observed in leukemia patients, and significantly increased survival in vivo.